醫渡科技(02158.HK)授出合共357萬股獎勵股份
格隆匯6月30日丨醫渡科技(02158.HK)發佈公告,於2025年6月30日,公司根據首次公開發售後股份獎勵計劃,通過發行新股份向115名獎勵承授人(包括114名僱員參與者及1名服務提供商)授出合共357萬股獎勵股份,佔於本公告日期全部已發行股份(不包括庫存股)約0.34%。
首次公開發售後股份獎勵計劃旨在爲獲選定參與者(包括僱員參與者及服務提供商)提供獲取公司所有權權益的機會,藉以鼓勵獲選定參與者爲公司及股東整體利益積極工作,提高公司及其股份的價值。透過首次公開發售後股份獎勵計劃,公司可以靈活方式留任、激勵、獎勵、酬謝、補償合資格人士及╱或向彼等提供福利。董事會認爲,該等獎勵將確保公司的長期利益,並激勵獎勵承授人爲公司的發展作出貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.